HYDROCORTISONE 1% RECTAL SUPPOSITORIES REQUIRE CLINICALS

HYDROCORTISONE 1% RECTAL SUPPOSITORIES REQUIRE CLINICALS to demonstrate efficacy of the product, the agency told Parke-Davis in denying its ANDA suitability petition. FDA stated that suppository products were not included in previous DESI notices that ruled effective 0.5% topical hydrocortisone and hydrocortisone acetate products. "A suppository preparation involves not only a different dosage form but also a different route of administration from the preparations described in these notices," the agency explained. FDA continued: "A suppository is inserted beyond the sphincter muscle, so that the amount of drug available in the anogenital area to treat dermatoses is unclear. Thus, the effectiveness of a suppository preparation on dermatoses is not apparent from a finding of effectiveness of a topically applied ointment, cream, lotion or spray and investigations to demonstrate effectiveness are necessary." Parke-Davis cited four products as potential reference listed drugs: Reid-Rowell's Proctocort 1% topical rectal cream and Cortenema 100 mg/60 ml hydrocortisone rectal enema; and Reed & Carnrick's Proctofoam HC (hydrocortisone acetate/pramoxine HCl) 1% rectal foam and Cortifoam 10% rectal foam aerosol. FDA asserted that the safety and efficacy data for any one of the four products could not be extended to hydrocortisone suppositories. The agency noted that Proctocort and Proctofoam HC have a different dosage form and route of administration than hydrocortisone suppositories. Furthermore, "Proctofoam HC is a combination product comprised of two active ingredients, not one as in the proposed product," FDA said. The active ingredient in Proctocort also differs from that in Parke-Davis' proposed product. The agency stated that Cortifoam and Cortenema are approved for different indications than that of Parke-Davis' proposed hydrocortisone product. Parke-Davis is seeking an indication for "relief of the inflammatory manifestations of corticosteroid-responsive dermatoses of the anogenital area." Cortifoam and Cortenema are indicated as adjunctive therapy in the treatment of ulcerative proctitis. In addition, FDA said Cortifoam contains hydrocortisone at a 10-fold greater concentration than the Parke-Davis product.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Korea Pre-Review Consultations Help Accelerate R&D

 
• By 

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.

US FDA Pediatric Adcomm To Examine HPV, Flu, Dengue Vaccines: No News Is Good News?

 
• By 

Pediatric Advisory Committee will weigh the FDA's recommendation that routine safety monitoring continue for Merck & Co's Gardasil and Sanofi's Fluzone and Dengvaxia despite a political climate that has been unkind to vaccines.

Medicaid Changes Could Have Major Impact on Recent Coverage Improvements

 
• By 

Insurance trade groups warned that the Big Beautiful Bill destabilize Medicaid and result in the largest ever roll-back in health care coverage in the US.